Evidence-based recommendations for the use of WBC-reduced cellular blood components. - Test2 - elhamkhani - TriplyDB

Evidence-based recommendations for the use of WBC-reduced cellular blood components.

Evidence-based recommendations for the use of WBC-reduced cellular blood components.

http://www.wikidata.org/entity/Q34405086

about

Leucoreduction of blood components: an effective way to increase blood safety?Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective Role of Leukoreduction of Packed Red Blood Cell Units in Trauma Patients: A Review Pharmaco-economics of blood transfusion safety: review of the available evidence.The war on cancer: a report from the front lines Ensuring blood safety and availability in the US: technological advances, costs, and challenges to payment--final report.Infectious and immunologic consequences of blood transfusion Recommendations from the Tuscan Transfusion System on the appropriate use of solvent/detergent-inactivated fresh-frozen plasma Recommendations for the transfusion of red blood cells.Recommendations for the transfusion of plasma and platelets.How we treat cytomegalovirus in hematopoietic cell transplant recipients.How important is transfusion avoidance in 2013?Using basic ethical principles to evaluate safety efforts in transfusion medicine.Umbilical cord blood transfusions for prevention of progressive brain injury and induction of neural recovery: an immunological perspective.The residual risk of transfusion-transmitted cytomegalovirus infection associated with leucodepleted blood components.Management of CMV, HHV-6, HHV-7 and Kaposi-sarcoma herpesvirus (HHV-8) infections in patients with hematological malignancies and after SCT.A comparison of PLT collections from two apheresis devices.Management of cytomegalovirus infection in haemopoietic stem cell transplantation.Leucoreduction helps to preserve activity of antioxidant barrier enzymes in stored red blood cell concentrates.Pre-storage leucocyte depletion and transfusion reaction rates in cancer patients.WBC-containing allogeneic blood transfusion and mortality: a meta-analysis of randomized controlled trials.Evaluation of HTLV-I removal by filtration of blood cell components in a routine setting.

P2860

Q26771857-D991C8D1-8F8F-443E-8AE8-A761EB7385EA Q28388806-E42E9FDA-6C9B-4CD7-B279-4FB756C4589E Q33707808-762B8C21-738D-4FEF-88CB-88B0E2517AC1 Q34803014-C04A4537-5238-4CD8-94BC-D0EE79F8F5F8 Q35103643-9F4FFDB5-08C9-48DB-B3BC-EA02AC23FC94 Q35194576-6F4BAB96-CF74-4307-8160-91699B961486 Q35804510-D5C2BF60-C255-4EFD-BB82-1FF019EEFE3E Q37062415-F86F7624-276B-412E-ADFD-F6089BB3EDEF Q37119693-7DE2BDE5-36C3-4C9E-8A6D-05E26FE2ACBB Q37209117-5D9AC5E2-AA42-46B6-95F1-990089AE9CFC Q37237427-89314F54-E2FE-4D93-B6A0-3F8A4F548EB2 Q38088956-D0D40D5E-9AE2-4340-82ED-D552D3BE2905 Q38148756-CB4C35D3-9E38-4012-BEF9-E8D2F58DD8C4 Q40192959-917ACAA5-A9ED-42B1-91AD-45482BBC24B8 Q41100504-11660EB8-823D-4E12-8106-620535111467 Q44189939-39E49F24-5E93-4A25-99CF-56B14100C187 Q44704386-D1960509-DF88-4D0A-BD53-66A621C4D60D Q44714539-D8125AEB-2251-452A-B2F5-D712ABCF8895 Q50436820-FA6F0EA3-7CEC-4417-8D25-257D40B935FA Q50774708-096D509E-2FA1-427A-B507-9657DF529FC0 Q53859947-5AEADF88-2575-48FB-8F6D-2A1902A8F538 Q54736313-F28C5203-4E37-4FB2-B2EF-912EDAA659FB

P2860

Evidence-based recommendations for the use of WBC-reduced cellular blood components.

http://www.wikidata.org/entity/Q34405086

description

2001 nî lūn-bûn

@nan

2001 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2001 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2001年の論文

@ja

2001年論文

@yue

2001年論文

@zh-hant

2001年論文

@zh-hk

2001年論文

@zh-mo

2001年論文

@zh-tw

2001年论文

@wuu

name

Evidence-based recommendations for the use of WBC-reduced cellular blood components.

@ast

Evidence-based recommendations for the use of WBC-reduced cellular blood components.

@en

Evidence-based recommendations for the use of WBC-reduced cellular blood components.

@nl

type

label

Evidence-based recommendations for the use of WBC-reduced cellular blood components.

@ast

Evidence-based recommendations for the use of WBC-reduced cellular blood components.

@en

Evidence-based recommendations for the use of WBC-reduced cellular blood components.

@nl

prefLabel

Evidence-based recommendations for the use of WBC-reduced cellular blood components.

@ast

Evidence-based recommendations for the use of WBC-reduced cellular blood components.

@en

Evidence-based recommendations for the use of WBC-reduced cellular blood components.

@nl

P1433

Q34405086-9F374E38-4DE8-4DCF-A144-FFD6B6E36142

P1476

Q34405086-D255E229-4CCD-457B-9B29-36A239B0F373

P2093

Q34405086-1E2DCFBB-0A0E-41FC-8B4C-ABA6F2899ADE

Q34405086-20AC776A-0E58-48D5-A566-76AD4B95B2BB

Q34405086-21F40C14-F11E-4B10-BB7A-4553AC4D207E

Q34405086-48E16D3A-D1D2-422D-99FF-7E12402688D7

Q34405086-5CE76665-C094-43FA-8FB7-DC82BF50526E

Q34405086-6BAC94BD-A9C4-4467-BCE6-0AC745347413

Q34405086-6EB190F7-F9A6-4314-83AB-737561DA2D25

Q34405086-94973054-86FC-4219-9C52-6B090567502B

Q34405086-A0935A08-D3F5-4A47-945F-0A844E28D9C3

Q34405086-E8D9DB5D-3D9C-49DA-ACC9-3CBC82C1DDAF

P2860

Q34405086-09348A51-86CF-46C5-B5FE-B22BED2ACCA0

Q34405086-0AD901F0-B2B6-4760-9B83-FC431B1D54E5

Q34405086-1F9330E4-AE74-407A-8D9B-35DAC1E64653

Q34405086-29BEFC49-7695-409F-A8EE-EC94219ECF58

Q34405086-306DB4E9-0443-437A-A3B3-02CCBB0AF567

Q34405086-40E24EDF-1D05-443B-8CFE-0B385DC3A49C

Q34405086-49E4277D-AAE4-4120-8DB7-2A5DEB314C90

Q34405086-4FB24EE5-B482-4ACE-9E64-883D6E1F0C53

Q34405086-5A557D79-584B-45E9-BF75-44FF86ABF830

Q34405086-70A568D8-5C81-4918-8759-37326245C5E9

P304

Q34405086-7A73C989-A34F-44F2-8EC0-4E31CF90131A

P31

Q34405086-93FB801B-341E-4E60-A5FE-F9DD834C62E8

P356

Q34405086-1823B3FA-49A7-4BE4-B866-119D5439755B

P433

Q34405086-596BE050-031C-49E8-B6BC-210521A606C4

P478

Q34405086-6EF8643E-32F7-4429-A08F-23CE1A32F3F3

P577

Q34405086-9E8B3118-B210-4D59-8A9A-9A25BA9AB755

P5875

Q34405086-EAC0DE7D-55FA-451A-8073-09E4AD702B07

P698

Q34405086-52089408-5086-4640-B3D1-6D7FBFB88255

P356

J.1537-2995.2001.41101310.X

P1433

P1476

Evidence-based recommendations for the use of WBC-reduced cellular blood components.

@en

P2093

D H Yawn

http://www.w3.org/2001/XMLSchema#string

D T Eastlund

http://www.w3.org/2001/XMLSchema#string

H A Oberman

http://www.w3.org/2001/XMLSchema#string

J E Godwin

http://www.w3.org/2001/XMLSchema#string

J P Cummings

http://www.w3.org/2001/XMLSchema#string

K A Matuszewski

http://www.w3.org/2001/XMLSchema#string

K P Crookston

http://www.w3.org/2001/XMLSchema#string

P J DeChristopher

http://www.w3.org/2001/XMLSchema#string

R A Sacher

http://www.w3.org/2001/XMLSchema#string

T A Ratko

http://www.w3.org/2001/XMLSchema#string

P2860

Transfusion medicine. First of two parts--blood transfusion

The role of the plasma from platelet concentrates in transfusion reactions.

Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions.

Are allogeneic blood transfusions acceptable in elective surgery in colorectal carcinoma?

Pathophysiology of febrile nonhemolytic transfusion reactions.

Leukocyte reduction of blood components: public policy and new technology.

The cytomegalovirus-"safe" blood product: is leukoreduction equivalent to antibody screening?

Deleterious clinical effects of transfusion-associated immunomodulation: fact or fiction?

Universal WBC reduction: the case for and against.

Prevention of primary transfusion-associated cytomegalovirus infection in bone marrow transplant recipients by the removal of white cells from blood components with high-affinity filters.

P304

1310-1319

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1046/J.1537-2995.2001.41101310.X

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

41

http://www.w3.org/2001/XMLSchema#string

P577

2001-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11743434

http://www.w3.org/2001/XMLSchema#string

P698

11606834

http://www.w3.org/2001/XMLSchema#string